Cytofluorimetric detection of the multidrug resistance (MDRI-associated membrane protein (P-170) was performed at the time of diagnosis in 158 patients with acute myeloid leukemia using the C219 monoclonal antibody (MoAb). In 108 of these cases the JSBl MoAb was also tested. An improved histogram subtraction analysis, based on curve fitting and a statistical test was applied t o distinguish antigen-positive from antigen-negative cells. A marker was considered positive when more than 20% of the cells were stained. At onset, P-170 was detected in 43Y0 of cases with C219 and in 73% of cases with JSB1. There was a strict correlation between C219 and JSBl positivity, as all C219+ cases were also positive for JSBl MoAb ( P < .001). No relationship was found between sex, age, organomegaly, and MDR phenotype. Significant correlation was found between CO7 and both C219 and JSBl expression ( P < .001 and .001, respectively). C219-negative phenotype was more often associated with a normal karyotype (24 of 55 with P = .030). Rhodamine 123 (Rh123) staining and flow cytometry analysis showed a significantly decreased mean fluorescence in 51 C219+ and 38 JSBl+ patients compared t o 42 MDR nega-EVERAL recent studies have indicated that poor re-S sponse to therapy in acute myeloid leukemia (AML) may be correlated with a high level of expression of Pglycoprotein (PGP) both in treated and newly diagnosed patients. The multidrug resistance gene (MDR 1) encodes for a transmembrane glycoprotein (P-170) that acts as an adenosine triphosphate dependent efflux pump, capable of expelling cytostatic drugs from the cytosol." At present, a clinical significant level of P-170 expression has not yet been defined,I3-l4 because PGP is also detectable in normal tissues. Besides, discrepant results are related to methodological problems for quantitative measurement in heterogeneous leukemic cells. The immunohistochemical techniques are widely used for the determination of P-170 on a single cell level,S.lS.16 but quantitation is often hampered by subjective assessment of the examiner. A few studies have applied flow cytometry to the detection of PGP in AMLI7,l8: this may reflect problems related to the precise semiquantitative measurement of low level antigen expression that is frequently found in AML. In this study, we established a reliable flowcytometric method for the quantitation of low-level PGP expression and showed that P-170 phenotype, depicted by two monoclonal antibodies (MoAbs) (C219 and JSBl), was associated with a poor outcome of intensive antileukemic treatment.
S sponse to therapy in acute myeloid leukemia (AML) may be correlated with a high level of expression of Pglycoprotein (PGP) both in treated and newly diagnosed patients. The multidrug resistance gene (MDR 1) encodes for a transmembrane glycoprotein (P-170) that acts as an adenosine triphosphate dependent efflux pump, capable of expelling cytostatic drugs from the cytosol." At present, a clinical significant level of P-170 expression has not yet been defined,I3-l4 because PGP is also detectable in normal tissues. Besides, discrepant results are related to methodological problems for quantitative measurement in heterogeneous leukemic cells. The immunohistochemical techniques are widely used for the determination of P-170 on a single cell level,S.lS. 16 but quantitation is often hampered by subjective assessment of the examiner. A few studies have applied flow cytometry to the detection of PGP in AMLI7,l8: this may reflect problems related to the precise semiquantitative measurement of low level antigen expression that is frequently found in AML. In this study, we established a reliable flowcytometric method for the quantitation of low-level PGP expression and showed that P-170 phenotype, depicted by two monoclonal antibodies (MoAbs) (C219 and JSBl), was associated with a poor outcome of intensive antileukemic treatment.
MATERIALS AND METHODS
Diagnosis of AML was made on bone marrow (BM) and peripheral blood smears routinely stained and evaluated according to the revised French-American-British (FAB) criteria." The diagnosis of AML-MO was made following the guidelines proposed by the same group.2o
Immunophenotyping. Double color immunofluorescence analysis of surface antigens was performed using combinations of phycoerythrin (PE) and fluorescein isothyocyanate (FITC) conjugate MoAbs. The panel included anti-CD33 (My9-PE) and anti-CD13 tive ones (P < .001). The rate of first complete remission (CR) differed both between C219+ and C219-cases and between JSB1+ and JSB1-ones (30.9% w 71.190 and 35.4% w 93.1%. respectively, P < ,001). Of the 21 C219+ patients who had yielded a first CR, 19 (90.4%) relapsed, compared with 28 of 64 (43.7%) C219-patients ( P < .001). Of the 28 JSB1+ patients in first CR, 17 (60.7%) relapsed relative t o 8 (29.6%) of 27 JSB1-ones ( P = .021). A higher rate of relapses among MDR+ compared with MDR-patients was observed both for C219 and JSBl MoAbs taken separately (C219 8OYo w 44%; JSBl 52% w 27%). with no relationship t o age. The survival rates (Kaplan-Meyer method) were significantly shorter both in C219+ patients and in JSBI+ cases ( P < .001). Disease-free survival curves followed this same trend. The combination (C219-JSB1') identified a subset of patients with an intermediate outcome compared t o C219 positive cases. The prognostic value of both markers (C219 and JSB1) was confirmed in multivariate analysis. These results suggest that the assessment of MDR phenotype by flow cytometry may be an important predictor of treatment outcome.
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, all purchased from Becton Dickinson (Mountain View, CA); anti-CD14 (FMC-17-FlTC) supplied by Seralab (Sussex, UK). Mononuclear cell fractions were separated from heparinized BM samples by Ficoll-Hypaque gradient centrifugation (Sigma, St Louis, MO). All samples contained at least 80% of blasts. Before immunostaining, cells were treated with 2.5% human AB serum to minimize Fc receptor binding and washed twice with phosphate-buffered saline (PBS) afterwards. Cells (1 X 107/mL) were then incubated at 4°C for 30 minutes with the MoAbs at saturation concentrations and washed twice with PBS. Analysis was performed on an Epics Profile flow cytometer (Coulter). Samples with isotypematched control antibodies were processed in parallel. A minimum of 8,000 events for each specimen was acquired. Intracytoplasmic and nuclear stains on cytospin preparations included: nuclear terminal deoxynucleotidyl transferase, cCD3, myeloperoxidase (MPO), and cCDl3, as previously described.*','* Immunofluorescence was evaluated by optical examination using a Zeiss microscope equipped with an epifluorescence set, a barrier filter set for blue fluorescence, and a lOOx phase contrast objective (Zeiss, Gottingen, Germany). Compared to a simple subtraction of histograms, this approach clearly increased the sensitivity of the flow cytometric determination of low level PGP expression (Fig 1) . To avoid contamination of residual nonleukemic myeloid cells, the threshold of positivity was set to a conventional 20%. PGP function was examined by measuring the retention of the fluorescent substrate Rhodamine 123 (Rh 123) in the absence of P-170 inhibition. Cells were incubated with 150 ng/ mL of Rh 123 (Sigma) for 15 minutes at 37°C in RPMI, washed and incubated in 10 mL of RPMI with 7% fetal bovine serum at 37T. Afterwards, the samples were taken at 0, 15, 30, 60, 90, 120, and 180 minutes of incubation, washed at 4"C, and analyzed immediately. Flow cytometric analysis was performed as previously described. Rhodamine 123 (Rh123) fluorescence was measured as for FITC. P-170 function. Karyotype analysis.
Statistical anafysis.
Karyotype analysis was performed on aspirated BM cells, as previously described?'
The relationship of the expression of P-170 to quantitative parameters (age, blood counts, percent of marrow blasts) were studied by analysis of variance. Relationstups of PGP reactivity (considered as positive or negative) to patients' characteristics and response to treatment were analyzed by the chi-square test (or Fisher's exact test when either group included fewer than 20 cases). The percentages of cells stained for P-170 were also used as quantitative data to examine their linear relationship to overall survival and continuous complete remission (CCR). A t-test for significance of the slope of regression line was performed. Because each patient category was assigned to a specific therapeutic protocol, the effects of treatment were specifically factored before significance Survival parameters are expressed in weeks. was assigned. Survival and CCR rates curves were plotted according to the method of Kaplan-Meyer. Survival was measured from the date of diagnosis to the date of death or last follow-up. Remission duration was calculated from the date of CR until relapse. Six patients who underwent autologous or allogeneic BM transplantation were censored at the time of BM infusion. For comparison of remission duration or survival patterns of two or more groups, the logrank test was applied. Multivariate analysis was performed using the Cox regression model to analyze the simultaneous effect of the different variables. The variables for which univariate analysis had shown a significant association were studied.
RESULTS
We studied 158 newly diagnosed AML cases, admitted at our unit, between June 1990 and June 1994 (Tables 1 and 2 ). Patients had a median age of 56 years (15 to 81) with a performance status 5 2 (World Health Organization grading system). Induction treatments were differentiated according to age. For 98 patients aged above 60 years, induction scheme consisted of high doses of cytosine arabinoside (ARA- Differences between total green fluorescence intensities from control and test samples were often small both for C219 and JSBl MoAb. The mean fluorescence intensity of staining both with C219 (2.1 2 5) and JSB-1 (4.1 ? 6) MoAbs in our AML cases shifted between 82261 Dox 6 mean (1.8 2 2) and 8226Dox 40 one (3.8 ? 2). In any case, no correlation was found between mean fluorescence and both biological features and clinical outcome in our patients. Fifty BM specimens from normal donors were used as control group: in all cases, amount of PGP measured by flow cytometry with both MoAbs (C219 and JSB-1) was always lower than 20% (range 1% to 15%). With this cutoff point, the application of curve fitting and subtraction analysis revealed PGP expression in 68 of 158 (43%) and in 79 of 108 (73%) patients, using C219 and JSB-1 MoAbs, respectively. There was no correlation between PGP expression and sex, age, extramedullary disease, or marrow blast percentage. A leukocyte count greater than 50 X 109L was significantly associated with JSBl positivity (P = .01). With respect to the FAB subgroups, strict correlations were noted both between C219 negativity and M3 subtype (only one of 16 cases was positive; P = .04) and between JSB 1 positivity and MO-M4-M5 subtypes (P = .015). There was a close association between PGP expression and CD7 positivity, as 91 of 158 samples had similar patterns of staining with C219 (P < .001), and 78 of 108 with JSBl (P = .001). Expression of CD14 correlated with JSBl positivity (53 of 79 with P = .04, Table 3 ). There was a strict relationship among C219 and JSBl positivity: all the C219+ cases were positive for JSB 1 (P < .001). Karyotypes were obtained in 84 cases: 29 were C219' and 55 were C219-. Of the MDR' cases, 6 had a normal karyotype and 23 were abnormal: 6 had monosomy 7 or del (7)(q22), 3 had a translocation [t(9;22)], 3 had a translocation [t(9; 1 l)] or del ( 11) Rh123 accumulation studies were performed in 50 normal donors and in 131 patients (51 C219+, 38 JSB-lC, and 42 negative for both MoAbs). Mean fluorescence intensities appeared to be significantly decreased, at 3 hours after Rh123 loading, either in C219 or in JSB-1 positive cases with respect to both normal donors and PGP negative ones as shown in .001 and P = .02, respectively). The survival rates (Fig 3A  and B) were significantly shorter both in C219+ patients and in JSBI' ones ( P < ,001). The effects of PGP expression on CR rate and survival were analyzed after stratification into two age groups (young, 5 4 5 yrs; old, >45 years): PGP was confirmed independent prognostic factor (Fig 4A and  B) because the statistical differences were maintained within the two groups. The remission duration was studied in 85 patients for C219 and in 55 cases for JSBl: PGP negative disease [C219-JSB1-] showed a trend toward longer remission ( P < .O1 for C219; P = .02 for JSB 1 ; Fig 5A and B) . prognostic factor in acute leukemia^.^*^,'." However, only a few studies have applied flow cytometry for the detection of PGP in AML patients.'6332 This reflects methodological problems related to the precise quantitation of low-level antigen expression. To increase the sensitivity of the flow cytometric method, we applied a combined procedure based both on cumulative subtraction and curve modeling of the histograms through the Immuno-4 software. This approach allowed us to detect a low P-170 expression that accounted for drug resistance in the leukemic blasts, as previously pointed
In our study, AML cases were considered positive if more than 20% of the cells were stained, although the percentage of positive cells ranged from 1% to 100%. Overall, according to this cut-off criterion, 43% and 73% of patients were found to express PGP using C219 and JSBl MoAbs, respectively. Each of these MoAbs recognizes a different antigenic determinant. It is noteworthy that MoAb C219, which is widely used for immunocytochemistry and Westem blotting, cross reacts with the protein encoded by the MDR-3 gene34 and with other gene products. 35 On the other hand, JSB-1, an IgGl isotype, identifies an independent, strongly conserved cytoplasmic epitope present on mammalian MDR-1, but cross-reacts with several poorly characterized proteins. Because both of these antibodies react with intracellular epitopes, permeabilization is required and hence this cross-reactive proteins are likely to be detected. The higher JSBl positivity in our study, with respect to C219, might be because of the ability of JSBl to detect low, but significant quantities of PGP on the leukemic cells.36 Even more, JSB-1 has a lower kd than C219 for PGP and this is reflected by the different staining intensity. The binding properties of other MoAbs to external epitopes of PGP (MRK-16, 4E3) were recently r e p~r t e d .~~.~~ MRK-16, an IgG2a isotype antibody, was described both to significantly increase intracellular accumulation and to potentiate the cy- or FAB classification (with the exception of M3). From a cytogenetic point of view, we found a clear correlation between [t(l5; 17)], and PGP negativity (9 of 9). Our results are also in agreement with Paietta et a14* who reported significantly lower levels of PGP expression in 35 patients with FAB M3 leukemia. With respect to the other cytogenetic classes, we found that those karyotypic abnormalities associated with poor outcome, such as monosomy 7 andor complex karyotypes, are frequently combined with MDR phenotype. In fact the encoding MDRl gene is located on the long arm of chromosome 7 (7 q21.1) and might be disregulated or overe~pressed~' during alterations of this chromosome. Conversely, abnormalities such as t(8;21) or inv( 16) are very rarely positive for P-170 glycoprotein. Finally, we found a significant correlation between normal karyotypes and MDR negativity ( P = ,030). As regards phenotypic analysis, we observed a strict correlation between CD7 expression and PGP positivity: in fact, the combined expression of CD7 and PGP (either with C219 or JSBI) identifies a subset of AML patients with very poor prognosis. Miwa et aI4' strengthened our findings showing that CD7 and CD34 were the only markers significantly associated with MDRl and mRNA expression ( P < .01). In addition, we found that the coexpression of CD7 and/or CD14 on the PGP' cells might identify a further subset with peculiar biological features such as immaturity, monocytic differentiation, and bad prognosis. As shown in Tables 1 and 2 , and in Figs 3 and 4 , a signifi- cantly lower CR rate and overall survival duration were observed in the two MDR positive populations, C219+ and JSBl', as compared with the MDR negative ones (P < .001 in all cases). Even more, within the MDR+ class, we identified a subset of patients C219-JSB1' with an intermediate outcome with regard to CR rate, overall survival and CCR. These results might be ascribed to the greater ability of JSB 1, compared to C219 MoAb, to detect low but significant levels of PGP on leukemic blasts. A significantly higher relapse rate in the PGP+ population was also observed either as a whole or in the subgroup who obtained a first CR ( P < .001 for C219, P = .02 for JSB1). Thus, we can postulate a primary role of MDR phenotype, not only in predicting chemoresistance, but also early relapse. Despite C219 and JSB-1 crossreact with different, poorly characterized, cellular proteins, in our study the MDR phenotype correlates well with functional assays and with the clinical outcome. This point has been evidenced both by the analysis of PGP with Rh123 uptake and by the separate analysis of the single (C219-JSBl+) versus the double (C219+JSB1+) positive cases. Furthermore, multivariate analysis showed that the MDR phenotype was an independent variable relative to prognosis. An impressive difference in CR rates, survival, and CCR was observed between the MDR+ versus the MDR-patients: this gap was maintained when young and old patients were analyzed separately. Finally, C219 and JSB 1 still retained statistical significance as regards CR duration when analyzed in multivariate analysis. We conclude that: (1) the MDR phenotype is confirmed as having a very poor prognostic value; (2) from a methodological point of view, we standardized a novel flow cytometric technique feasible and very useful to detect low levels of PGP expression; 3) the combined use of two MoAbs allowed us to identify subsets of patients with different clinical outcome; (3) MDR phenotype is frequently associated with other poor prognostic factors such as CD7, CD14, abnormal and/or complex karyotypes. In this view, AML-MO represents a paradigmatic example of the convergence of these unfavorable f e a t~r e s .~' .~~ Based on our experience, randomized clinical trials are warranted comparing conventional chemotherapy versus revertant agents plus chemotherapy.
